bims-evecad Biomed News
on Extracellular vesicles and cardiovascular disease
Issue of 2026–07–05
five papers selected by
Cliff Dominy



  1. Theranostics. 2026 ;16(13): 7367-7387
      The pathogenesis of myocardial ischemia-reperfusion (MI/R) injury is intricately linked to mitochondrial dysfunction occurring during both the ischemic and reperfusion phases. Through single-cell transcriptome analysis, we identified a subpopulation of HEY1-high expressing cardiomyocytes (HEY1+ CMs) characterized by superior mitochondrial homeostasis. To leverage this, we isolated P5CS-type or ATP5B-type functional mitochondria from a ΔΨm-high subpopulation, which was obtained via membrane potential sorting following dual overexpression in HEY1+ CMs, and subsequently encapsulated them within HEY1+ CM-derived exosomes to achieve stable, targeted delivery. We designed a responsive microneedle patch based on local copper/iron ion dynamics to enable the stage-specific release of these mitochondria within the ischemic or reperfusion microenvironments. In a Bama minipig MI/R model, this system significantly ameliorated cardiac function, reduced infarct size, and attenuated cardiomyocyte death. Mechanistically, the therapeutic strategy enhanced mitochondrial structural integrity and energy metabolic function. This study establishes a responsive, stage-specific mitochondrial delivery platform, offering a promising strategy for the precision treatment of ischemic heart disease.
    Keywords:  ATP5B; HEY1; Ischemia-reperfusion injury; Microneedles; P5CS
    DOI:  https://doi.org/10.7150/thno.123209
  2. Front Cardiovasc Med. 2026 ;13 1868328
       Background/purpose: Due to the complex pathological process of ischemic heart diseases (IHD), a single treatment strategy had limited efficacy. Multi-targeted synergy, precise delivery, and long-lasting effects were new directions for treatment. Engineering extracellular vesicles (EVs) had become a research hotspot in the field of IHD treatment due to their ability carrying therapeutic signaling molecules, precise tissue targeting capabilities, and excellent biocompatibilities. This systematic review focused on the modification methods, targeting strategies, and combined effects of multi-pathway synergy of engineered EVs in IHD treatment.
    Methods: Systematic searches were conducted in 8 databases. According to strict inclusion and exclusion criteria, the literature was screened, and relevant information was extracted based on the research purpose. Two researchers independently screened the literature, extracted information, and evaluated the quality of literatures.
    Results: A total of 50 animal studies were included. The existing studies mainly achieved the engineering modification of EVs through internal loading/knockdown, surface modification, membrane fusion, combination with biotechnological materials, and pre-treatment; and by using targeting peptides or specific antibodies modification, membrane fusion, and in situ cardiac delivery, to enhance their targeting enrichment abilities for ischemic myocardium. In terms of therapeutic effects, engineered EVs could exert beneficial effects on cardiac function through multiple pathways, such as alleviating myocardial fibrosis, inhibiting inflammatory responses, promoting angiogenesis, reducing cardiomyocyte apoptosis, and improving mitochondrial metabolism. The multi-modal therapy of engineered EVs presented a pyramid structure: improving cardiac function served as the foundation, ameliorating classical cardioprotective pathways constituted the primary pillars, and optimizing metabolic modulation represented supplementary.
    Conclusion: There was an intrinsic association between the multi-association therapeutic effects of engineered EVs and the modification methods. Currently, the modification strategies of engineered EVs formed a composite system of " internal cargo loading/knockdown of core signaling molecules + surface modification and membrane fusion to enhance targeting specificity + combination with bioengineering materials for local sustained release", which met the multiple needs of multi-targeted synergy, precise delivery, and long-lasting effects. This systematic review provided key theoretical basis and practical guidance for constructing a multifunctional EVs delivery system for treating IHD and accelerating its clinical translation and application.Systematic Review Registration: https://www.crd.york.ac.uk/, identifier PROSPERO CRD420261393475.
    Keywords:  IHD; engineered extracellular vesicles (engineered EVs); extracellular vesicles (EVs); multi-modal therapy; targeting strategy
    DOI:  https://doi.org/10.3389/fcvm.2026.1868328
  3. Mol Med. 2026 Jul 02.
       BACKGROUND: Carbon monoxide poisoning (COP) induces systemic hypoxia and oxidative stress-related injury, leading to myocardial injury and persistent cardiac dysfunction. However, reliable biomarkers for monitoring long-term cardiac sequelae and therapeutic responses remain lacking. Extracellular vesicles (EVs), which reflect the molecular status of their cells of origin, may serve as candidate biomarkers for organ-specific injury. This study investigated whether cardiac EV proteins capture COP-induced myocardial and mitochondrial dysfunction and reflect the therapeutic effects of hyperbaric oxygen (HBO) therapy.
    METHODS: A rat model of COP was established with or without HBO treatment. Cardiac function was assessed by echocardiography, and myocardial injury was evaluated using histological, ultrastructural, and biochemical analyses. Cardiac-enriched EVs isolated from ex vivo whole-heart perfusate were used for global proteomic profiling. Candidate differentially abundant proteins were analyzed with emphasis on pathways related to mitochondrial dynamics, mitochondrial energy metabolism, calcium handling, and myocardial contractility. Key EV-associated and tissue proteins were further validated, and selected candidates were examined in serum-derived EVs as preliminary targeted circulating EV validation.
    RESULTS: COP induced significant cardiac dysfunction, as evidenced by reduced ejection fraction and fractional shortening, together with histological myocardial injury, all of which were attenuated by HBO treatment. Proteomic analysis demonstrated that COP reshaped the cardiac EV proteome in a manner consistent with mitochondrial abnormalities, altered calcium-handling protein profiles, and impaired myocardial contractile function. These EV proteomic alterations were enriched in pathways related to mitochondrial dynamics, calcium signaling, and cardiac contractile regulation. Specifically, COP was associated with dysregulation of mitochondrial dynamics regulators, including optic atrophy type 1 (Opa1) and mitochondrial fission protein 1 (FIS1), as well as calcium-handling proteins such as ryanodine receptor 2 (Ryr2) and phospholamban (Pln). Ultrastructural and biochemical analyses showed mitochondrial cristae disruption, altered mitochondrial fusion-fission protein profiles, mitophagy-related protein changes, and pyroptosis-associated signaling in cardiac tissue following COP, whereas HBO mitigated these abnormalities. Notably, EV-associated Opa1 and FIS1 were associated with COP-related alterations in mitochondrial dynamic balance, whereas EV-associated Ryr2 and Pln were associated with impaired myocardial contractile parameters. Additional analysis of EV proteins related to mitochondrial function and ATP energy production further supported COP-associated mitochondrial energy metabolism-related protein remodeling. Targeted analysis of serum-derived EVs further showed that selected calcium-handling proteins, including Ryr2 and Pln, were detectable in circulating EVs and exhibited COP-associated changes consistent with cardiac tissue alterations. These findings support selected cardiac-enriched EV proteins as candidate molecular readouts of COP-associated myocardial, mitochondrial, and contractile abnormalities.
    CONCLUSIONS: Cardiac EV proteomic remodeling reflects COP-associated mitochondrial and contractile abnormalities and captures the therapeutic effects of HBO. These findings identify cardiac-enriched EV proteins as candidate molecular readouts of myocardial injury and treatment response, providing a cardiac-enriched EV discovery framework for future blood-based biomarker development. The observed alterations in mitochondrial dynamics-, mitochondrial energy metabolism-, and calcium-handling-related proteins provide hypothesis-generating insight into molecular pathways associated with COP-induced cardiac dysfunction. Further validation using circulating EV proteomics, biomarker classifier analyses, and dedicated redox proteomics will be required to establish clinical utility and redox-regulated mechanistic relevance.
    Keywords:  Calcium signaling; Carbon monoxide poisoning; Cardiac dysfunction; Cardiac extracellular vesicles; Hyperbaric oxygen therapy; Mitochondrial dynamics; Proteomics
    DOI:  https://doi.org/10.1186/s10020-026-01534-0
  4. JCI Insight. 2026 Jul 02. pii: e200422. [Epub ahead of print]
      Extracellular vesicles (EVs)-mediated inter-organ communication represents a promising frontier in transplant immunology; however, its role in cardiac allograft rejection remains poorly characterized. We performed proteomic profiling of plasma-derived EVs in a rat heterotopic heart transplantation model and identified a distinct liver-predominant protein signature during acute rejection, with Antithrombin III (ATIII) emerging as a top candidate. Functional validation revealed that pharmacological EV inhibition intensified systemic and intragraft inflammation, whereas adeno-associated virus (AAV)-mediated silencing of hepatic ATIII directly accelerated allograft rejection. Conversely, AAV-mediated hepatocyte-specific ATIII overexpression attenuated rejection pathology, reduced immune cell recruitment, and markedly prolonged median graft survival. This protective effect was achieved without evidence of coagulopathic complications, indicating an immunomodulatory mechanism beyond ATIII's canonical anticoagulant function. Mechanistically, ATIII overexpression was associated with upregulation of heme oxygenase-1 (HO-1) in the liver and suppression of proinflammatory cytokine expression in the graft. These findings highlight hepatocyte-derived EVs as important mediators of a liver-heart signaling axis in transplant rejection, and further implicate the protein ATIII as a contributor to this axis. Our study reveals a therapeutically targetable liver-heart signaling axis in transplant rejection, whereby enhancing liver-derived ATIII or its downstream pathways (such as HO-1) could attenuate acute cardiac allograft rejection.
    Keywords:  Cardiology; Cardiovascular disease; Immunology; Immunotherapy; Transplantation
    DOI:  https://doi.org/10.1172/jci.insight.200422
  5. Theranostics. 2026 ;16(13): 7698-7714
       RATIONALE: Ischemic stroke is sexually dimorphic. Biological sex can influence injury progression and response to treatment. Extracellular vesicles (EV) derived from three-dimensional (3D) human mesenchymal stem cell aggregates (3D-EV) are a promising candidate as a treatment, but their efficacy across these biological variables and in vivo behavior needs to be characterized. This study evaluated whether 3D-EV therapy enhances recovery following ischemic stroke in female and male models using ultra-high-field MRI and their influence on structural, ionic, and metabolic recovery.
    METHODS: A preclinical model of transient middle cerebral artery occlusion was used to longitudinally evaluate the efficacy of ultrasmall superparamagnetic iron oxide (USPIO)-labeled 3D-EV or saline at reperfusion through intra-arterial injection. MRI was performed at 21.1 T, which included T2-weighted, diffusion-weighted imaging, gradient-recalled echo imaging, and ²³Na chemical shift imaging. Proton magnetic resonance spectroscopy (¹H-MRS) was used to quantify changes in lactate, N-acetylaspartate, creatine, and choline within peri-infarct tissue. Imaging and behavioral outcomes were assessed over 21 days.
    RESULTS: USPIO-labeled 3D-EV resulted in localized hypointense contrast in the ischemic striatum, indicating delivery of treatment. T2-weighted MRI showed progressive lesion reduction, with a trend toward better recovery in females. ²³Na MRI revealed reduced sodium accumulation, with earlier ionic normalization in 3D-EV-treated animals. Diffusion recovery was observed with sex-dependent trajectories. ¹H-MRS showed lower lactate concentrations and preservation of other metabolites in EV-treated females. Behavioral differences were not significant.
    CONCLUSIONS: 3D-EV therapy showed trends toward structural, ionic, and metabolic recovery following an ischemic insult. Ultra-high-field MRI and MRS can provide sensitive biomarkers to resolve these differences and support 3D-EV as a potential cell-free therapeutic candidate for ischemic stroke.
    Keywords:  aging; diffusion MRI; extracellular vesicles; ischemic stroke; mesenchymal stem cells; sex differences; sodium MRI
    DOI:  https://doi.org/10.7150/thno.129188